Human spondin 2 (SPON2) is a secreted ECM protein that belongs to the mindin / F-spondin family, comprises N-terminal FS1 and FS2 domains and C-terminal thrombospondin type 1 repeats (TSR). The FS domain mediates integrin binding, which is required for inflammatory cell recruitment and T-cell priming. The TSR domain recognizes pathogen-associated molecular patterns and initiates innate immune responses. In addition, SPON2 protein has been shown to promote the outgrowth and adhesion of embryonic hippocampal neurones and to inhibit angiogenesis. Human SPON2 also plays a role in infectious diseases and cancer pathogenesis. Recent data indicated that SPON2 acts as a novel anti-hypertrophic ECM protein that prevents maladaptive remodeling and the transition to HF by blocking AKT/glycogen synthase kinase 3β (GSK3β) and transforming growth factor (TGF)-β1–Smad signalling.

Full-length mature human SPON2 cDNA (27–331aa, derived from BC036341) was constructed with codon optimization and expressed with a small T7-His-TEV cleavage site Tag (29aa) fusion at its N-terminal. This protein is expressed in E.coli as inclusion bodies. The final product was refolded using our unique “temperature shift inclusion body refolding” technology and chromatographically purified.

1. May be used for in vitro SPON2 mediated cardiac hypertrophy regulation study with this protein as either coating matrix protein or soluble factor.

2. May be used for FBLN2 protein-protein interaction assay.

3. Potential diagnostic biomarker protein for prostate cancer.

4. As antigen for specific antibody production.